Skip to main content
SpringerLink
Log in

Echocardiographic Quantification of Left Ventricular Mass: Prognostic Implications

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for adverse cardiac and cerebrovascular events. Despite this well-known association, the lack of a standardized approach for the quantification and the monitoring of LVH regression has limited its use as a primary risk factor that can be easily clinically targeted. Echocardiography has become the most widespread tool used for the quantification of LVH. With advances in this technology, echocardiographic quantification of LVH has improved and reference standards are being used to determine the clinical implications of LVH regression. In this article, we aim to provide a current appraisal of LVH with a focus on presenting the current clinical methods used to accurately detect LVH, the prognostic implications of these findings, and help develop a therapeutic target for clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as follows: • Of importance •• Of major importance

  1. Kannel WB, Gordon T, Castelli WP, et al.: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1970, 72:813–822.

    CAS  PubMed  Google Scholar 

  2. Carini G, Circo A, Dovellini E: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001, 38:1829–1835.

    Article  PubMed  Google Scholar 

  3. Ghali J, Liao Y, Simmons B, et al.: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992, 117:831–836.

    CAS  PubMed  Google Scholar 

  4. Schillaci G, Verdecchia P, Porcellati C, et al.: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000, 35:580–586.

    CAS  PubMed  Google Scholar 

  5. McLenachan JM, Henderson E, Morris KI, et al.: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987, 317:787–792.

    CAS  PubMed  Google Scholar 

  6. Casale PN, Devereux RB, Kligfield P, et al.: Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985, 6:572–580.

    Article  CAS  PubMed  Google Scholar 

  7. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.

    Article  CAS  PubMed  Google Scholar 

  8. Germain P, Roul G, Kastler B, et al.: Inter-study variability in left ventricular mass measurement: comparison between M-mode echocardiography and MRI. Eur Heart J 1992, 13:1011–1019.

    CAS  PubMed  Google Scholar 

  9. Lang RM, Bierig M, Devereux RB, et al.: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440–1463.

    Article  PubMed  Google Scholar 

  10. • Mor-Avi V, Lang RM: The use of real-time three-dimensional echocardiography for the quantification of left ventricular volumes and function. Curr Opin Cardiol 2009, 24:402–409. This is an informative review on application of RT3DE in clinical practice.

    Article  PubMed  Google Scholar 

  11. Mor-Avi V, Sugeng L, Weinart L, et al.: Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation 2004, 110:1814–1818.

    Article  PubMed  Google Scholar 

  12. Takeuchi M, Nishikage T, Mor-Avi V, et al. : Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and M-mode measurements. J Am Soc Echocardiogr 2008, 21:1001–1005.

    Article  PubMed  Google Scholar 

  13. Bluemke DA, Kronmal RA, Lima JA, et al.: The relationship between left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008, 52:2148–2155.

    Article  PubMed  Google Scholar 

  14. Okwuosa TM, Hampole CV, Ali J, et al.: Left ventricular mass from gated SPECT myocardial perfusion imaging: comparison with cardiac computed tomography. J Nucl Cardiol 2009, 16:775–783.

    Article  PubMed  Google Scholar 

  15. Milani RV, Lavie CJ, Mehra MR, et al.: Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 2006, 97:959–963.

    Article  PubMed  Google Scholar 

  16. Nadour W, Biederman RW: Is left ventricular hypertrophy regression important? Does the tool used to detect it matter? J Clin Hyperten (Greenwich) 2009, 11:441–447.

    Article  Google Scholar 

  17. •• Fagard RH, Celis H, Thijs L, et al.: Regression of left ventricular mass by antihypertensive treatment. Hypertension 2009, 54:1084–1091. This is a recent large clinical meta-analysis evaluating the therapeutic effect of antihypertensive therapy on clinical outcomes.

    Article  CAS  PubMed  Google Scholar 

  18. Artham SM, Lavie CJ, Milani RV, et al.: Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009, 52:153–167.

    Article  PubMed  Google Scholar 

  19. Devereux RB, Wachtell K, Gerdts E, et al.: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350–2356.

    Article  CAS  PubMed  Google Scholar 

  20. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41–46.

    Article  PubMed  Google Scholar 

  21. Cuspidi C, Esposito A, Negri F, et al.: Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens 2008, 21:458–463.

    Article  PubMed  Google Scholar 

  22. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104:1615–1621.

    Article  CAS  PubMed  Google Scholar 

  23. Devereux RB, Dahlof B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.

    Article  CAS  PubMed  Google Scholar 

  24. Devereux RB, Palmieri V, Liu JF, et al.: Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention for Endpoint Reduction study. J Hypertens 2002, 20:1445–1450.

    Article  CAS  PubMed  Google Scholar 

  25. Kannel WB, Schatzkin A: Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985, 5:141B–149B.

    Article  CAS  PubMed  Google Scholar 

  26. Verdecchia P, Reboldi G, Gattobigio R, et al.: Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003, 41:218–223.

    Article  CAS  PubMed  Google Scholar 

  27. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831–1838.

    Article  CAS  PubMed  Google Scholar 

  28. Solomon SC, Applebaum E, Manning WJ, et al.: Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530–537.

    Article  CAS  PubMed  Google Scholar 

  29. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006, 113:1213–1225.

    Article  CAS  PubMed  Google Scholar 

  30. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996, 275:1507–1513.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University of Chicago Medical Center, 5841 South Maryland Avenue, MC 5084, Chicago, IL, 60637, USA

    Rajiv S. Swamy & Roberto M. Lang

Authors
  1. Rajiv S. Swamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto M. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajiv S. Swamy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swamy, R.S., Lang, R.M. Echocardiographic Quantification of Left Ventricular Mass: Prognostic Implications. Curr Cardiol Rep 12, 277–282 (2010). https://doi.org/10.1007/s11886-010-0104-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-010-0104-y

Keywords

Search

Navigation